Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial

By K. Margolis, D. Bonds, R. Rodabough, L. Tinker, L. Phillips, C. Allen, T. Bassford, G. Burke, J. Torréns, B. Howard and 1 more. Diabetologia, 2004

603 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/e885d4c0cef86982bce82c780eac9a5f1bcfdac7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Peter J. Schmidt
2. R. Eckel

In Genetics

1. Peter J. Schmidt
2. R. Eckel

In Reproductive Medicine

1. Peter J. Schmidt

Citations in the corpus

• The 2012 Hormone Therapy Position Statement of The North American Menopause Society (2012, positive): “93) in the incidence of T2DM requiring treatment, which indicates 15 fewer cases per 10,000 women per year of therapy.(69) A similar statistically significant risk reduction was also noted in the Heart and Estrogen/Progestin Replacement Study trial (HR, 0.”
• The metabolic syndrome. (2008, background): “Nevertheless, estrogen replacement in postmenopausal women has been shown to improve many components of the MetS, such as abdominal adiposity, HDL-C, and fasting glucose (461–464) and to lower the incidence of T2D (462, 465, 466).”